Academic Journal
Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.
| Τίτλος: | Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. |
|---|---|
| Συγγραφείς: | Ali AS; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Grönberg M; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Federspiel B; Department of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Scoazec JY; Department of Biopathology, Institut Gustave Roussy, Villejuif, France., Hjortland GO; Department of Oncology, Oslo University, Oslo, Norway., Grønbæk H; Department of Hepatology & Gastroenterology, Aarhus university Hospital, Aarhus, Denmark., Ladekarl M; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Langer SW; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Welin S; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden., Vestermark LW; Department of Oncology, Odense University Hospital, Odense, Denmark., Arola J; Pathology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Österlund P; Department of Oncology, Helsinki University Hospital and Helsinki University, Helsinki Finland.; Department of Oncology, Tampere University Hospital, Tampere, Finland., Knigge U; Department of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark., Sorbye H; Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway., Grimelius L; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Janson ET; Department of Medical Sciences, Section of Endocrine Oncology, Uppsala University, Uppsala, Sweden. |
| Πηγή: | PloS one [PLoS One] 2017 Nov 07; Vol. 12 (11), pp. e0187667. Date of Electronic Publication: 2017 Nov 07 (Print Publication: 2017). |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: San Francisco, CA : Public Library of Science |
| Ιατρικοί όροι (MeSH): | Carcinoma, Neuroendocrine/*metabolism , Gastrointestinal Neoplasms/*metabolism , Pancreatic Neoplasms/*metabolism , Tumor Suppressor Protein p53/*metabolism, Carcinoma, Neuroendocrine/drug therapy ; Carcinoma, Neuroendocrine/pathology ; Gastrointestinal Neoplasms/drug therapy ; Gastrointestinal Neoplasms/pathology ; Ki-67 Antigen/metabolism ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/pathology ; Aged ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Neoplasm Metastasis ; Prognosis |
| Περίληψη: | Background: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) are aggressive, rapidly proliferating tumors. Therapeutic response to current chemotherapy regimens is usually short lasting. The aim of this study was to examine the expression and potential clinical importance of immunoreactive p53 protein in GEP-NEC. Materials and Methods: Tumor tissues from 124 GEP-NEC patients with locally advanced or metastatic disease treated with platinum-based chemotherapy were collected from Nordic centers and clinical data were obtained from the Nordic NEC register. Tumor proliferation rate and differentiation were re-evaluated. All specimens were immunostained for p53 protein using a commercially available monoclonal antibody. Kaplan-Meier curves and cox regression analyses were used to assess progression-free survival (PFS) and overall survival (OS). Results: All tumor tissues were immunoreactive for either one or both neuroendocrine biomarkers (chromogranin A and synaptophysin) and Ki67 index was >20% in all cases. p53 immunoreactivity was only shown in 39% of the cases and was not found to be a prognostic marker for the whole cohort. However, p53 immunoreactivity was correlated with shorter PFS in patients with colorectal tumors (HR = 2.1, p = 0.03) in a univariate analysis as well as to poorer PFS (HR = 2.6, p = 0.03) and OS (HR = 3.4, p = 0.02) in patients with colorectal tumors with distant metastases, a correlation which remained significant in the multivariate analyses. Conclusion: In this cohort of GEP-NEC patients, p53 expression could not be correlated with clinical outcome. However, in patients with colorectal NECs, p53 expression was correlated with shorter PFS and OS. Further studies are needed to establish the role of immunoreactive p53 as a prognostic marker for GEP-NEC patients. |
| References: | Mod Pathol. 2001 May;14(5):397-403. (PMID: 11353048) Cancers (Basel). 2012 Jan 16;4(1):11-30. (PMID: 24213223) Mod Pathol. 2011 Sep;24(9):1248-53. (PMID: 21552211) Endocr Relat Cancer. 2013 Aug 19;20(5):649-57. (PMID: 23845449) Oncogene. 2014 Dec 11;33(50):5706-15. (PMID: 24292676) Am J Clin Pathol. 2006 Dec;126(6):856-65. (PMID: 17074692) Neuroendocrinology. 2016;103(2):186-94. (PMID: 26731334) Oncogene. 2015 Jan 29;34(5):589-99. (PMID: 24469052) Am J Surg Pathol. 2016 Sep;40(9):1192-202. (PMID: 27259015) Nat Cell Biol. 2013 Jan;15(1):2-8. (PMID: 23263379) Diagnostics (Basel). 2015 Apr 08;5(2):119-76. (PMID: 26854147) Pancreas. 2010 Aug;39(6):799-800. (PMID: 20664477) Genes Cancer. 2011 Apr;2(4):466-74. (PMID: 21779514) J Korean Med Sci. 2006 Feb;21(1):35-9. (PMID: 16479062) Mod Pathol. 2008 Aug;21(8):937-42. (PMID: 18500258) Neuroendocrinology. 2017;104(1):85-93. (PMID: 26943788) Ann Oncol. 2013 Jan;24(1):152-60. (PMID: 22967994) Cancer. 2014 Sep 15;120(18):2814-23. (PMID: 24771552) Cancer Med. 2015 Jan;4(1):75-83. (PMID: 25354498) Ann Surg Oncol. 2016 May;23 (5):1721-8. (PMID: 26678407) Acta Oncol. 2014 Oct;53(10):1284-97. (PMID: 25140861) J Pathol. 2011 Jan;223(2):116-26. (PMID: 21125670) Clin Cancer Res. 2004 Feb 1;10(3):947-57. (PMID: 14871972) |
| Substance Nomenclature: | 0 (Ki-67 Antigen) 0 (Tumor Suppressor Protein p53) |
| Entry Date(s): | Date Created: 20171108 Date Completed: 20171128 Latest Revision: 20181113 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC5675414 |
| DOI: | 10.1371/journal.pone.0187667 |
| PMID: | 29112960 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1932-6203 |
|---|---|
| DOI: | 10.1371/journal.pone.0187667 |